Clinical and Genomic Risk to Guide the Use of Adjuvant Therapy for Breast Cancer

TAILORx established the role of the 21-gene predictor of genetic risk in ascertaining treatment for women with hormone-receptor–positive, human epidermal growth factor receptor 2–negative breast cancer. Clinical risk factors provided additional prognostic information for women with intermediate gene...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	The New England journal of medicine 2019-06, Vol.380 (25), p.2395-2405
Hauptverfasser:	Sparano, Joseph A, Gray, Robert J, Ravdin, Peter M, Makower, Della F, Pritchard, Kathleen I, Albain, Kathy S, Hayes, Daniel F, Geyer, Charles E, Dees, Elizabeth C, Goetz, Matthew P, Olson, John A, Lively, Tracy, Badve, Sunil S, Saphner, Thomas J, Wagner, Lynne I, Whelan, Timothy J, Ellis, Matthew J, Paik, Soonmyung, Wood, William C, Keane, Maccon M, Gomez Moreno, Henry L, Reddy, Pavan S, Goggins, Timothy F, Mayer, Ingrid A, Brufsky, Adam M, Toppmeyer, Deborah L, Kaklamani, Virginia G, Berenberg, Jeffrey L, Abrams, Jeffrey, Sledge, George W
Format:	Artikel
Sprache:	eng
Schlagworte:	Adjuvant therapy Adjuvants Adult Age Age Factors Aged Algorithms Antineoplastic Agents, Hormonal - therapeutic use Breast cancer Breast Neoplasms - drug therapy Breast Neoplasms - genetics Breast Neoplasms - surgery Cancer therapies Chemotherapy Chemotherapy, Adjuvant Clinical trials Confidence intervals Disease-Free Survival Endocrine therapy Epidermal growth factor Estrogen Antagonists - therapeutic use Female Gene Expression Profiling Humans Medical prognosis Medical research Middle Aged Neoplasm Recurrence, Local - genetics Neoplasm Recurrence, Local - prevention & control Oncology Premenopause Prognosis Proportional Hazards Models Prospective Studies Receptor, ErbB-2 Risk Factors Statistical analysis Tamoxifen Tamoxifen - therapeutic use Womens health
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Beschreibung
Zusammenfassung:	TAILORx established the role of the 21-gene predictor of genetic risk in ascertaining treatment for women with hormone-receptor–positive, human epidermal growth factor receptor 2–negative breast cancer. Clinical risk factors provided additional prognostic information for women with intermediate genetic risk.
ISSN:	0028-4793 1533-4406
DOI:	10.1056/NEJMoa1904819